Search
Search Results
-
Real-world comparison of fidaxomicin versus vancomycin or metronidazole in the treatment of Clostridium difficile infection: a systematic review and meta-analysis
PurposeThere is a lack of real-world evidence of the comparative effectiveness of fidaxomicin versus vancomycin or metronidazole for treating...
-
European Practice for CDI Treatment
Clostridioides difficile infection (CDI) remains a significant cause of morbidity and mortality worldwide. Historically, two antibiotics...
-
Bezlotoxumab during the first episode of Clostridioides difficile infection in patients at high risk of recurrence
PurposeTo describe a cohort with a high risk of recurrence who received bezlotoxumab during the first episode of Clostridioides difficile infection...
-
Recurrent Clostridioides difficile Infection: Current Clinical Management and Microbiome-Based Therapies
Clostridioides difficile is one of the most important causes of healthcare-associated diarrhea. The high incidence and recurrence rates of C. difficile ...
-
Extended-pulsed fidaxomicin versus vancomycin for Clostridium difficile infection: EXTEND study subgroup analyses
Poor outcomes following Clostridium difficile infection (CDI) have been associated with advanced age, presence of cancer and C . difficile ...
-
Extended-pulsed fidaxomicin versus vancomycin in patients 60 years and older with Clostridium difficile infection: cost-effectiveness analysis in Spain
The cost of treating Clostridium difficile infection (CDI) in Spain is substantial. Findings from the randomised, controlled, open-label, phase 3b/4...
-
Immunization Strategies Against Clostridioides difficile
Clostridioides difficile (C. difficile) infection (CDI) is an important healthcare but also a community-associated disease. CDI is considered a...
-
Impact of the use of local fidaxomicin treatment algorithms for managing Clostridium difficile infection in hospitalized patients in southeastern United States
BackgroundClostridium difficile -associated diarrhea (CDAD) is a major public health threat that results in increased length of stay, hospital...
-
Five-year Pan-European, longitudinal surveillance of Clostridium difficile ribotype prevalence and antimicrobial resistance: the extended ClosER study
Clostridium difficile infection (CDI) has been primarily treated with metronidazole or vancomycin. High recurrence rates, the emergence of epidemic...
-
Clostridioides difficile Biofilm
Clostridioides difficile infection (CDI), previously Clostridium difficile infection, is a symptomatic infection of the large intestine caused by the...
-
Antimicrobial resistance in Clostridioides (Clostridium) difficile derived from humans: a systematic review and meta-analysis
BackgroundClostridioides ( Clostridium ) difficile is an important pathogen of healthcare- associated diarrhea, however, an increase in the occurrence...
-
Genomic epidemiology and transmission dynamics of recurrent Clostridioides difficile infection in Western Australia
Recurrent cases of Clostridioides difficile infection (rCDI) remain one of the most common and serious challenges faced in the management of CDI. The...
-
Economic Burden of Clostridioides difficile Infection in European Countries
Clostridioides difficile infection (CDI) remains a considerable challenge to healthcare systems worldwide. Although CDI represents a significant...
-
Fidaxomicin for the treatment of Clostridium difficile infection (CDI) in at-risk patients with inflammatory bowel disease, fulminant CDI, renal impairment or hepatic impairment: a retrospective study of routine clinical use (ANEMONE)
Information is limited or lacking on fidaxomicin treatment of Clostridium difficile infection (CDI) in patients with inflammatory bowel disease,...
-
Reduction in urinary tract infections in patients treated with fecal microbiota transplantation for recurrent Clostridioides difficile infection
We performed an updated study to investigate the rates of urinary tract infections (UTIs) in patients with recurrent Clostridioides difficile ...
-
Correction to: Fidaxomicin for the treatment of Clostridium difficile infection (CDI) in at-risk patients with inflammatory bowel disease, fulminant CDI, renal impairment or hepatic impairment: a retrospective study of routine clinical use (ANEMONE)
The article “Fidaxomicin for the treatment of Clostridium difficile infection (CDI) in at-risk patients with inflammatory bowel disease, fulminant...
-
From signal transduction to protein toxins—a narrative review about milestones on the research route of C. difficile toxins
Selected findings about Clostridioides difficile (formerly Clostridium difficile ) toxins are presented in a narrative review. Starting with a...
-
Evaluation of a two step testing algorithm to improve diagnostic accuracy and stewardship of Clostridioides difficile infections
In response to national guidelines, we implemented a two-step testing algorithm for Clostridioides difficile in an effort to improve diagnostic...
-
Antibiotic Resistances of Clostridioides difficile
The rapid evolution of antibiotic resistance in Clostridioides difficile and the consequent effects on prevention and treatment of C. difficile...
-
Antimicrobial resistance in Clostridioides difficile
Antimicrobial resistance (AMR) in Clostridioides difficile remains a significant threat to global healthcare systems, not just for the treatment of C....
